Biogen’s hopes that one of its established multiple sclerosis drugs might also help stroke sufferers have been dashed. Natalizumab – best known as MS drug Tysabri - failed to show any benefits ...

Biogen, Inc. is a biopharmaceutical company ... Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM ...

Biogen has finalised a $900 million payment ... and meals to induce them to prescribe the MS drugs Avonex (interferon-beta-1a), Tysabri (natalizumab), and Tecfidera (dimethyl fumarate) between ...

Cambridge-based biotech Biogen Idec, the maker of the multiple sclerosis drug Tysabri, linkurl:announced;http://investor.biogenidec.com/phoenix.zhtml?c=148682&p=irol ...

With its move to MIT’s Volpe Center in Kendall Square, the drugmaker is consolidating its local footprint from three buildings to one.

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure ...

Balancing risk and benefit Biogen’s recombinant humanized monoclonal antibody, natalizumab (TYSABRI®), mediates lymphocyte and monocyte cell adhesion and transendothelial migration via the ...

Lower sales of Biogen’s key multiple sclerosis (MS) drugs like Tecfidera and Tysabri were partially offset by higher revenues from new drugs. Sales of spinal muscular atrophy (SMA) drug ...

Analysts on Wall Street project that Biogen Inc. (BIIB ... suggests that 'Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Total' will likely reach $394.22 million. The estimate indicates ...